American Heart Association

12/10/2025 | Press release | Distributed by Public on 12/10/2025 04:06

Uterine fibroids linked to elevated heart disease risk

Uterine fibroids linked to elevated heart disease risk

Heart disease risk may be substantially higher among women with uterine fibroids compared to those without, finds new study in the Journal of the American Heart Association

Research Highlights:

  • Long-term heart disease risk among women diagnosed with uterine fibroids was more than 80% higher than in women without uterine fibroids, according to a 10-year study of more than 2.7 million U.S. women.
  • The elevated heart disease risk among those with uterine fibroids persisted among all races and ages but was particularly strong in women younger than 40.
  • Researchers said more studies are needed to better understand and confirm the relationship between having uterine fibroids and increased heart disease risk - for now, these findings suggest women diagnosed with fibroids may benefit from enhanced attention to heart health and risk factor management.

Embargoed until 4 a.m. CT/5 a.m. ET Wednesday, Dec. 10, 2025

DALLAS, Dec. 10, 2025 - Long-term heart disease risk in women diagnosed with uterine fibroids was more than 80% higher than in women without fibroids, according to new independent research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.

Fibroids are predominately benign growths that develop from the muscle tissue of the uterus. The U.S. Office of Women's Health notes that as many as 20% - and possibly up to 80% - of women will develop fibroids by the time they reach age 50.

"Nearly 26 million pre-menopausal women in the U.S. are impacted by uterine fibroids and many do not experience any symptoms. Yet despite the high prevalence, fibroids are understudied and poorly understood," said study author Julia D. DiTosto, M.S., a Ph.D. Candidate in Epidemiology at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. "Some studies have shown that fibroids and cardiovascular disease share biological pathways, including the growth of smooth muscle cells, the excessive buildup of fibrous connective tissue, calcification and inflammatory responses."

DiTosto noted that those findings have been hindered by limitations including small study sample sizes that lacked diversity and insufficient study design.

"We set out to address these critical gaps using a large, diverse dataset with extended follow-up," she said. "Our findings suggest that fibroids may serve as an important marker for identifying women at elevated cardiovascular risk, with sustained increased risk persisting up to 10 years after diagnosis."

Researchers looked at a U.S. database of health information from 2000 to 2022. They studied more than 450,000 females (average age 41 years) with fibroids compared to nearly 2,251,000 females who had not been diagnosed with the fibroids. Over the next decade, researchers monitored for incidences of coronary artery disease (including heart attack), cerebrovascular disease (stroke and related conditions) and peripheral artery disease.

They found:

  • After 10-years of follow-up, women with fibroids were at higher risk for all three major conditions (coronary artery, cerebrovascular and peripheral artery diseases).
  • The risk of developing cardiovascular disease was 81% higher among those women with fibroids compared to those without.
  • At 10 years, more than 5.4% of women with fibroids had experienced a cardiovascular event compared to 3% of women without fibroids.
  • Women diagnosed with uterine fibroids were at increased heart disease risk across all racial and ethnic groups (white, Black, Hispanic and Asian groups).
  • Among younger women, under age 40, the risk for cardiovascular disease was 251% higher (or more than 3.5 times more likely) in those with fibroids compared to those without fibroids.

"The strength of the relationship between heart disease risk and uterine fibroids was striking," DiTosto said. "However, it's important to note that more research is needed to confirm these findings in other populations before formal changes are made to cardiovascular risk assessment guidelines. In the meantime, these results support having thoughtful conversations between women and their providers about heart health in the context of a fibroid diagnosis."

"This study highlights yet another aspect in the unique factors that impact women in regard to the leading cause of death among them - cardiovascular disease," said Stacey E. Rosen, M.D., FAHA, volunteer president of the American Heart Association and senior vice president of women's health and executive director of the Katz Institute for Women's Health of Northwell Health in New York City. "It also is an opportunity to recognize the very important role all of a woman's health care clinicians can play in her overall health, including heart health. Because many women may use annual "well-woman" visits to their gynecologist or their general practitioner as their primary point of care, these visits offer exceptional opportunities that go beyond gynecologic health. These findings linking fibroids to heart disease support the need to discuss the bigger picture that considers ways to identify and reduce cardiovascular disease risk, even among those women who may not have any other apparent risk factors."

Among the limitations of the study, fibroids may not have been diagnosed yet in women included in the comparison group. While the researchers tried to account for possible underdiagnosis of fibroids, the limitation may have impacted the results to some extent.

Study details, background and design:

  • The study included 2,701,062 females, average age of 41 years - 450,177 individuals with uterine fibroids matched to 2,250,885 controls without fibroids
  • Researchers at the University of Pennsylvania studied inpatient, outpatient and pharmacy claims from commercially insured individuals from 2000 to 2022 from Optum's de-identified Clinformatics® Data Mart Database.
  • Uterine fibroids were identified using ICD-9/10, CPT, or HCPCS codes, requiring either >1 inpatient/outpatient claim ≥1 day apart, or 1 fibroid claim preceded by transvaginal ultrasound or pelvic MRI within 30 days.
  • The outcome was first-time major atherosclerotic cardiovascular disease diagnosis including coronary artery disease, cerebrovascular disease and peripheral artery disease, ascertained using ICD-9/10 or CPT/HCPCS codes.
  • Models adjusted for sociodemographic factors (age, race/ethnicity), cardiovascular risk factors (smoking, obesity, sleep apnea, diabetes, hyperlipidemia, hypertension), mental health conditions (depression, anxiety), reproductive/obstetric history (parity, pregnancy complications, polycystic ovary syndrome (PCOS), infertility), cancer, health care utilization and medication use.

Co-authors, disclosures and funding sources are listed in the manuscript.

Studies published in the American Heart Association's scientific journals are peer-reviewed. The statements and conclusions in each manuscript are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here.

###

Additional Resources:

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.

For Media Inquiries and American Heart Association Expert Perspective: 214-706-1173

Cathy Lewis: [email protected]

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and stroke.org

American Heart Association published this content on December 10, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on December 10, 2025 at 10:07 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]